Possis RX Heart Catheter Approval, Anticipation Of AiMI Data Boost Stock

Possis Medical's receipt of PMA supplement approval for coronary use of its AngioJet Rheolytic XMI-RX rapid exchange thrombectomy catheter helped propel the firm's stock ahead 12% in May to $28.49